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Abstract The mutant Cu/Zn Superoxide dismutase (SOD1) 
associated with familial amyotrophic lateral sclerosis (FALS) 
with a 2 bp deletion was produced in two protein expression 
systems. The mutant SOD1, expressed as a fusion protein in E. 
colt, had fanmunoreactivity to an anti-human SOD1 antibody but 
no SOD activity. It was more susceptible to proteolysis and its 
immunoreactivity decreased more rapidly than the wild type. The 
mutant SOD1, expressed in Cosl cells, was not detected by 
either SOD activity staining or Western blot analysis, although 
expression of its mRNA was confirmed. These results suggest 
that the mutant SOD1 is seriously unstable in mammalian cells. 
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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fetal neurodegen-
erative disorder that primarily involves motor neurons [1]. 
The familial form of ALS (FALS) is known to consist of 
10-15% total ALS [2]. About 20-25% of all FALS families 
have mutations in the gene coding Cu/Zn Superoxide dismu-
tase (SOD1) [3]. We previously reported a pedigree of FALS 
with 2 bp deletion in the 126th codon of the SOD1 gene [4], 
which has its origin in the small Japanese islands of Oki [5]. 
This mutation is predicted to cause a frameshift and to gen-
erate premature termination in the 130th codon of the SOD1 
gene [6]. In this family, the patients and clinically non-affected 
members with the mutation showed a reduction in SOD1 
activity in red blood cells (RBCs) by 70% in the patients 
and 30% in the non-affected members with the mutation 
[7,8]. We failed to find evidence of the presence of the mutant 
SOD1 protein in postmortem brain tissue and RBCs from one 
patient belonging to this FALS pedigree, while reverse tran-
scription (RT)-polymerase chain reaction (PCR)-single strand 
conformational polymorphism (SSCP) analysis showed an ad-
ditional mRNA from the mutant SOD1 gene [8]. These results 
led us to investigate the stability of the mutant SOD1, because 
the mutant SOD1 in this family is proposed to be seriously 
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unstable [4]. We constructed two kinds of expression systems 
in Escherichia coli and mammalian cells to produce the re-
combinant SOD1 protein which was compatible with the 
frameshift mutation. In this paper, several items of evidence 
concerned with the instability of the mutant SOD1 protein are 
presented. 
2. Materials and methods 
2.1. Materials 
The human SOD1 cDNA and mammalian expression vector, 
pYN3215, were kindly provided by Prof. K. Sato (Molecular Biology, 
Tottori University). Materials used in the present study were pGEM-
7Zf(+) (Promega, Madison, USA); Gene Taq, ISOGEN and deoxy-
ribonuclease (DNase) (Nippon Gene, Toyama, Japan); pMAL-cRI, 
amylose resin and factor Xa (New England BioLabs, Beverly, MA, 
USA); exonuclease III and mung bean nuclease (MBI Fermentas, 
Vilnius, Lithuania); human SOD1 (Sigma, St. Louis, MO, USA); a 
sheep anti-human SOD1 polyclonal antibody (The Binding Site, Bir-
mingham, UK); an anti-sheep IgG (H+L) antibody labeled with 
horseradish peroxidase (HRP) (ZYMED Laboratories, San Francisco, 
CA, USA); ECL (Amersham, Buckinghamshire, UK); and GenAMP 
(Perkin-Elmer, New Jersey, USA). All other chemicals were of reagent 
grade. 
2.2. Site directed PCR mutagenesis 
The mutant cDNA of the SOD1 was obtained by two subsequent 
PCR amplifications using one specific mutagenic primer and two uni-
versal primers [9]. The entire coding region of the human SOD1 was 
cloned into pUC19 (SODl-pUC19) and pGEM-7Zf(+) (SOD1-
pGEM7Zf). The first PCR primers were the mutagenic primer: 5'-
AAAGCAGATGACGGGCAAAGGTGG-3' (the wild-type se-
quence: TGACTTGGGC [4]) and T7 primer: 5'-TTGTAATAC-
GACTCACTATAG-3'. The first PCR reaction (20 μΐ) was performed 
in 2 ul of appended 10 X PCR buffer, 50 ng SODl-pGEM7Zf vector 
as a template, 200 μΜ dNTPs, 200 pM mutagenic primer, 200 pM T7 
primer, and 2.5 units Taq polymerase with 30 amplification cycles of 
1 min at 94°C, 1 min at 55°C and 1 min at 72°C. Then the first PCR 
products were hybridized with SODl-pUC19 and extended by Taq 
polymerase for 2 min at 72°C to obtain single strand mutant cDNA. 
The second PCR reaction (40 μΐ) was performed using T7 primer and 
reverse M13/pUC primer, 5'-TCACACAGGAAACAGCTATGAC-
3'. The open reading frame of the mutant cDNA was confirmed to 
have no misreading by sequencing. 
2.3. Construction of the expression vectors 
For the expression in E. coli, a commercial expression vector, 
pMAL-cRI, was used. In order to avert the incorporation of excess 
amino acids, the non-coding region ahead of the start codon in the 
SOD1 gene was deleted by exonuclease III and mung bean nuclease 
[10]. The wild-type and mutant SOD1 genes were inserted downstream 
of the malE gene which encoded the maltose binding protein (MBP) 
at 42 kDa (wt SODl-pMALcRI and del SODl-pMALcRI), and re-
sulted in the expression of MBP-SOD1 fusion proteins. 
The wild-type and mutant SOD Is were also cloned into the mam-
malian expression vector pYN3215 carrying the SRa promoter [11] 
(wt SODl-pYN3215 and del SODl-pYN3215). In this system, recom-
binant SOD Is were produced in the same manner as in human tissue. 
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2.4. Purification ofexpressed SODls in R. coli 
The host R. coli, XLl-Blue, was transformed with wt SOD1-
pMALcRI or del SODl-pMALcRI, and the transformed E. coli 
was treated with 1 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) 
for 5 h to induce the formation of the fusion proteins. The R. coli 
were lysed by sonication for 1 min on ice in lysis buffer containing 10 
mM sodium phosphate, 30 mM NaCl, 0.25% (w/w) Tween 20, 10 mM 
ß-mercaptoethanol, 10 mM EDTA, 10 mM EGTA, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 10 μ^ιηΐ soybean trypsin inhib-
itor at pH 7.O. Purification of the fusion proteins was performed by 
the following procedure: the lysates were treated with affinity chro-
matography with amylose resin; then the resin was washed 2 times 
with 3 bed volumes of the column buffer (10 mM sodium phosphate, 
30 mM NaCl, 1 mM sodium azide, 10 mM ß-mercaptoethanol, and 
1 mM EGTA at pH 7.0) with 0.25% Tween 20, and 2 times with 5 bed 
volumes of the column buffer without Tween 20; after that the fusion 
proteins were eluted with column buffer containing 10 mM maltose. 
To separate the SOD Is from the MBP, the fusion proteins were 
cleaved with factor Xa with a 4-h incubation in the cleavage mixture 
(20 μΐ) containing 2 μg proteins, 50 μ^ηιΐ factor Xa, 20 mM Tris-HCl, 
100 mM NaCl, 1 mM sodium azide, 10 mM ß-mercaptoethanol, and 
1 mM EGTA at pH 8.O. 
HRP was used as the second antibody, and the SOD Is binding to 
these antibodies were detected by the HRP detection system, ECL. 
2.7. Activity staining 
Cell-free extracts were electrophoretically separated on native linear 
gradient polyacrylamide gel (10-20%). Staining for SOD activity was 
performed according to the method described by Beauchamp and 
Fridovich [14]. 
2.8. RT-PCR-SSCP analysis for the mRNA of Cosl cells 
Total RNA was extracted from the transfected Cosl cells using 
ISOGEN and was treated with DNase to avoid contamination by 
plasmid DNA. Then reverse transcription to DNA using the reverse 
transcriptase, GenAMP, was performed. Reverse transcript products 
(10 μΐ) were added to 50 μΐ PCR reaction mixture containing Taq 
polymerase. PCR primers were 5'-GATGGTGTGGCCGATGTGTC-
TA-3' and 5'-TTCTACAGCTAGCAGGATAACA-3'. These primers 
hybridize a 252 bp part in the human SODl sequence [15] in which 
the segment of 2 bp deletion is contained. Conformational poly-
morphism of the PCR products, which were electrophoresed on 
12% polyacrylamide gel containing 5% glycerol at 4°C and 3 W over-
night, were detected by silver staining [16]. 
2.5. Expression in Cosl cells 
Cosl cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum. The cells were 
transfected with wt SODl-pYN3215 and/or del SODl-pYN3215 ac-
cording to the procedure of Chen and Okayama [12]. Then they were 
incubated at 37°C for 24 h. After renewal of the medium, the cells 
were further incubated for 24 h. Then they were washed three times 
with phosphate buffer saline (PBS) and collected. 
2.6. Western blot analyses 
Western blot analysis of the extracts of R. coli was performed with 
the samples after the affinity chromatography with or without cleav-
age by factor Xa. 
The transfected Cosl cells were homogenized with lysis buffer: 50 
mM Tris, 5 mM EDTA, 125 mM NaCl, 1 mM PMSF, and 10 μg/ml 
soybean trypsin inhibitor at pH 7.4. The homogenates were sonicated 
for 1 min on ice. 
The samples from the R. coli and Cosl cells were fractionated on 
native or sodium dodecyl sulfate (SDS) linear gradient 10-20% poly-
acrylamide gel electrophoresis (PAGE). Electrotransfer to the nitro-
cellulose membrane was performed by the method of Bjerrum and 
Shafer-Nielsen [13]. The antigen bound membrane was treated with 
PBS containing 0.5% Tween 20 and 5% skim milk (pH 7.4), prior to 
the addition of a sheep anti-human SODl polyclonal antibody as a 
primary antibody. An anti-sheep IgG (H+L) antibody labeled with 
3. Results 
3.1. Purification of expressed SODls in E. coli 
Because of premature termination due to the amber muta-
tion that was located on the 5' terminal of the start codon of 
the SODl gene, two protein bands, MBP (42 kDa) and MBP-
SOD1 fusion proteins (the wild type: 60 kDa or the mutant: 
57 kDa), were observed (Fig. 1, lanes 1-4). However, a single 
band was seen in Western blot analysis (lanes 6, 8). The esti-
mated molecular weight of the human erythrocyte SODl was 
16 kDa (lane 5). After cleavage by factor Xa, the wild-type 
SODl (18 kDa, lane 7) and the mutant SODl (15 kDa, lane 
9) were separated from the MBP. The larger molecular sizes 
of the recombinant SODls are accounted for by the fact that 
these SODls have an additional 17 amino acid residues at the 
N terminal of the proteins. 
In activity staining, the wild-type fusion SODl (lane 2) and 
the wild-type separated SODl (lane 3) showed SOD activity 
(Fig. 2). The wild-type separated SODl (lane 3) migrated to 
almost the same degree as the human erythrocyte SODl (lane 
1). On the other hand, the mutant fusion SODl (lane 4) and 
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Fig. 1. Purification of recombinant SODls expressed in R. coli. Fusion SODls were purified from crude extracts of R. coli using affinity chro-
matography, which were then cleaved with factor Xa. Each sample was separated on SDS-PAGE and the gels were stained with Coomassie 
blue (lanes 1-4) or detected with Western blot analysis (lanes 5-9). The amount of proteins applied were 30 μg (lanes 1, 3), 0.2 μg (lane 5) and 
1 μg (other lanes). Lanes: 1, crude extract of R. coli transformed by wt SODl-pMALcRI; 2, purified MBP-SOD1 (wild-type) fusion protein; 
3, crude extract of £ coli transformed by del SODl-pMALcRI; 4, purified MBP-SOD1 (mutant) fusion protein; 5, human erythrocyte SODl; 
6, purified MBP-SOD1 (wild-type) fusion protein; 7, separated wild-type SODl; 8, purified MBP-SOD1 (mutant) fusion protein; 9, separated 
mutant SODl. The immunoreactivity of the mutant SODl (lanes 8, 9) was about 3 times weaker than the wild-type SODl (lanes 6, 7). The 42 
kDa band in lane 5 was due to an impurity. 
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Fig. 2. Recombinant SOD Is separated by native PAGE. Recombinant SOD Is expressed in R coli were separated on native PAGE and the 
gels were stained with SODl activity (lanes 1-5) or detected with Western blot (lanes 6-8). The amounts of proteins applied were 0.2 μg (lanes 
1, 8) and 1 μg (other lanes). Lanes: 1, human erythrocyte SODl; 2, fusion wild-type SODl; 3, separated wild-type SODl; 4, fusion mutant 
SODl; 5, separated mutant SODl; 6, fusion mutant SODl; 7, separated mutant SODl; 8, human erythrocyte SODl. The mutant SOD Is had 
no SOD activity (lanes 4, 5). Approximate molecular weight of each protein was fusion wild-type SODl: 120 kDa, fusion mutant SODl: 60 
kDa, separated wild-type SODl: 30 kDa, and separated mutant SODl: 15 kDa. The fusion mutant SODl and the separated mutant SODl 
seem to be monomeric proteins. 
the mutant separated SODl (lane 5) revealed no SOD activ-
ity, though reactivity against the anti-human SODl polyclo-
nal antibody was observed (lanes 6, 7). The molecular weight 
of the separated mutant SODl was less than expected. 
3.2. Susceptibility of the SODls to proteolysis 
As shown in Fig. 3A, the degradation of the wild-type 
SODl was observed after the treatment with proteinase K 
at more than 100 ng/ml. On the other hand, the degradation 
of the mutant SODl was confirmed with 1 ng/ml proteinase 
K. 
3.3. Stability of the SODls with or without copper ions 
The wild-type SODl was stable during incubation at 22°C 
for 24 h, and the addition of C11SO4 had no significant effect 
on the immunoreactivity of SODl (Fig. 3B). In contrast, the 
immunoreactivity of the mutant SODl decreased during the 
24-h incubation. The addition of CUSO4 partly prevented this 
decrease. 
3.4. Expression in Cosl cells 
While the wild-type SODl was expressed in Cosl cells, 
judged from the results of activity staining and Western blot 
analysis, Cosl cells transfected with the mutant cDNA were 
revealed to have neither SOD activity nor immunoreactivity 
(Fig. 4A,B). We co-transfected with wt SODl-pYN3215 and 
del SODl-pYN3215, to yield heterodimeric SODl between 
the wild-type and mutant subunits. No activity band on the 
gels was observed except for the homodimer of the wild-type 
SODl and native Cosl SODl, and the heterodimer between 
the wild-type and Cosl SODl subunits (Fig. 4A). RT-PCR-
SSCP analysis revealed that there was mRNA due to the 
mutant SODl gene (Fig. 4C). 
4. Discussion 
Transgenic mice overexpressing the mutant SODl gene as-
sociated with FALS manifested clinically and pathologically 
motor neuron disease-like features [17,18]. This fact suggests 
that 'gain of function' results in motor neuron degeneration in 
FALS. It has been reported, however, that a high level of 
SODl activity was sometimes toxic, as in the case of the 
reoxygenated heart [19] or mouse epidermal cells [20], as 
well as a low level of SODl activity [21]. On the other 
hand, SODl-deficient mice revealed no manifestations of mo-
tor neuron disease [22]. We previously reported the absence of 
the mutant SODl protein in postmortem tissues from a FALS 
patient, despite the existence of mRNA due to the mutant 
SODl gene [8]. We referred to the possibility that the trun-
cated protein was immediately degraded [8]. Indeed, this mu-
tation of a 2 bp deletion was predicted to be a sole null 
mutation [2]. However, two possibilities still remain: the first 
is that the mutant SODl protein is seldom translated from 
mRNA, and the second is that the mutant SODl lacks im-
munoreactivity to the anti-human SODl polyclonal antibody 
used in the experiment. 
In the present study, the existence of the mutant SODl 
protein was confirmed when it was expressed as a MBP-
SOD1 fusion protein in E. coli, although it was more fragile 
than the wild-type SODl and probably lacked dimer forming 
ability. The fact that the presence of copper ions prevented the 
decrease of the mutant SODl in a proteinase free condition 
suggests the possibility that copper ions are concerned with 
the structural stability of the mutant SODl. We think perhaps 
that the mutant SODl, which binds less tightly to copper ions, 
alters its molecular structure after the release of copper ions, 
and that the structural alteration results in the reduction of 
SODl immunoreactivity. The monomer condition and struc-
tural alteration of the mutant SODl probably induce suscept-
ibility to attack by various proteinases. Cosl cells transfected 
with del SODl-pYN3215 showed neither immunoreactivity 
nor SOD activity. The presence of mRNA transcribed from 
the mutant SODl was confirmed by RT-PCR-SSCP analysis. 
We conclude that the mutant SODl hardly exists in mamma-
lian cells, although there is a slight possibility that the mutant 
SODl protein is not translated from the abnormal mRNA in 
mammalian cells. 
We previously reported that the level of copper ions of the 
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Fig. 3. Characterization of the mutant SODl. A: Susceptibility of the SODls to proteolysis. The purified fusion SODls were cleaved with fac-
tor Xa with proteinase K at final concentrations of 10 μ^ιηΐ, 1 μg/ml, 100 ng/ml, 10 ng/ml, or 1 ng/ml at 22°C for 4 h. The reaction mixtures 
were separated on SDS-PAGE. In the mutant SODl, each sample was applied on the gel at three-fold the wild-type SODl (wild type: 1 μg 
proteins and mutant: 3 μg proteins). The SODls were detected by Western blot analysis. Lanes: 1, proteinase K (none) as control; 2, 10 μg/ 
ml; 3, 1 μ^piύ; 4, 100 ng/ml; 5, 10 ng/ml; 6, 1 ng/ml of proteinase K. B: Stability of the SODls with or without copper ions. The separated 
SODls were incubated with or without 1 mM Q1SO4 at 22°C. Once in 6 h, mixtures were partly held and treated with sample buffer for SDS-
PAGE. In the mutant SODl, each sample was applied on the gel at three-fold the wild-type SODl as in A (wild type: 1 μg proteins and mu-
tant: 3 μg proteins). Then each sample was separated on SDS-PAGE. Detection of SODls was performed by Western blot analysis. All experi-
ments were performed at least three times and the same results were confirmed. Lanes: 1, 0 h (after factor Xa cleavage for 4 h); 2, 6 h; 3, 12 
h; 4, 18 h; 5, 24 h incubation. The immunoreactivity of the mutant SODl disappeared during 24-h incubation and the presence of copper ions 
partly prevented this decrease. Because the SODls were purified using affinity chromatography, this experiment was carried out under protein-
ase free condition. This decrease of the SODl immunoreactivity may come from spontaneous conformational alteration of the mutant SODl. 
brain from one patient belonging to this F A L S pedigree was 
about 1.9 times higher than in the control subjects [23]. Cop-
per ions have been reported to promote lipid peroxidation [24] 
and to catalyze formation of the highly reactive hydroxyl 
radical ( Ό Η ) from H2O2 [25]. The mixture of copper ions 
with H2O2 promotes site specific D N A damage [26,27]. Cyto-
toxic activity of copper ions was also reported in cell cultures 
[28-30]. It has been reported that the S O D l plays a role in 
intracellular copper buffering: overexpression of S O D l en-
hanced copper resistance, whereas a deletion of S O D l con-
ferred an increased sensitivity toward copper ions in Sacchar-
omyces cerevisiae. [28]. Our results seem to suggest that the 
mutan t S O D l itself can not be harmful to motor neurons. 
The metabolites of the mutan t protein, including copper 
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Fig. 4. Expression in Cosl cells. A: Activity staining. The wild-type and the mutant SODls were expressed in Cosl cells as described in Section 
2. Samples were separated on native PAGE. 20 μg protein extracts were applied in each lane. Lanes: 1, human erythrocyte SODl; 2-4, cells 
transfected with the SODl cDNA as follows: 2, wild type; 3, wild type and mutant; 4, mutant; 5, cells transfected with vector without SODl; 
6, untransfected cells. No activities were identified in Cosl cells transfected with del SODl-pYN3215, except for Cosl SODl (lane 4). While 
the heterodimeric SODls between the wild-type and the Cosl SODl subunits (lane 2) were seen, no activity suggesting a heterodimer between 
either the wild-type and mutant subunits or the mutant and the Cosl SODl subumts were observed (lanes 3, 4). B: Western blot analysis. 
Each sample (30 μg protein extracts) was electrophoretically separated on SDS-PAGE. Lanes: 1, cells transfected with the wild-type cDNA; 
2, cells transfected with the mutant cDNA; 3, untransfected cells; 4, human erythrocyte SODl. C: RT-PCR-SSCP analysis. The analysis was 
performed as described in Section 2. Lanes: 1, PCR products from the wild-type cDNA; 2, PCR products from the mutant cDNA; 3-5, RT-
PCR products from cells transfected with the cDNA as follows: 3, the wild type; 4, the mutant; 5, vector without SODl; 6, RT-PCR products 
from untransfected cells. In lanes 5 and 6, RT-PCR products were applied at five-fold those of lanes 1-4, because these signals of PCR prod-
ucts were weaker than those of lanes 1-4. 
ions, may play an important role in the neuronal death in 
F A L S . At least it appeared so in this pedigree. 
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